Uncategorized
Study highlights potential of alternative anti-inflammatory agent
A single postoperative injection of XG-102 was non-inferior to dexamethasone eye drops in the management of surgery-induced ocular inflammation in a phase 2 randomized, controlled trial. The study, which was carried out at six sites in France, randomized 145 eyes of 145 patients undergoing anterior or posterior segment surgery into three groups, receiving XG-102 (brimapitide, Xigen) 90 µg, XG-102 900 µg or dexamethasone eye drops administered four times a day for 21 days. XG-102 was administered by subconjunctival injection at the end of surgery.